article thumbnail

AIMS v. Garland: A Disappointment for Psilocybin Advocates, but Progressive Policy May Still be on the Horizon

Cannabis Law Report

Congress passed the RTT Act in 2018 to give qualifying patients access to investigational drugs outside of a clinical trial setting. Psilocybin successfully completed an FDA-approved Phase 1 clinical trial in 2019, and two companies, COMPASS Pathways and Usona, both currently have Phase 2 trials ongoing.

DEA 52
article thumbnail

First ethics at MAPS in question and now Australia’s Mind Medicine look to have some serious integrity issues too

Cannabis Law Report

Reporter Elise Worthington also investigates the dark side of this form of therapy where disturbing cases of abuse and malpractice are emerging in both clinical trials and the underground. She was a Harkness Fellow in Health Care Policy, a VicHealth Fellow in Health Promotion and an NHMRC Fellow in Suicide Prevention.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Cannabis & Dementia: New Study Explores Pot’s Potential for Treatment

Cannabis Info

In the Australian clinical study, cannabinoids will be extracted and delivered in a mouth spray, making it easier to be administered to the elderly. The clinical trial will be held over a 14-month period starting early next year. But it is significant that the clinical trials are taking place overseas.

article thumbnail

MAPS Is 36 Years Old – Doblin Provides Precis Timeline of the Organization

Cannabis Law Report

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. For over three decades, we’ve been working to achieve mass mental health throughout the United States, Canada, and Europe.

article thumbnail

Psychedelic Invest’s 100 Most Influential People in Psychedelics List

Cannabis Law Report

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Amanda Feilding, Countess of Wemyss and March is an English drug policy reformer, lobbyist and research coordinator. Andrew Yang.